On May 21, 2022, the shipment ceremony of the first batch of million doses of Walvax Biotechnology Co.Ltd(300142) 13 price pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as “13 price pneumonia vaccine”) was grandly held in Yuxi! Relevant leaders and guests from relevant departments of Yunnan Province, Yuxi Municipal Party committee and government, Yunnan Walvax Biotechnology Co.Ltd(300142) Co., Ltd. (hereinafter referred to as ” Walvax Biotechnology Co.Ltd(300142) “) and industry partners attended the ceremony.
On May 12, Walvax Biotechnology Co.Ltd(300142) ( Walvax Biotechnology Co.Ltd(300142) . SZ) announced that Yuxi Watson, a holding subsidiary, recently received the first purchase order of 1 million doses of 13 price pneumonia conjugate vaccine authorized by the Ministry of health of Morocco, and Yuxi Watson will start supplying 13 price pneumonia conjugate vaccine to Morocco according to the order. Today, with the sound of the order, the batch of vaccines were officially shipped and embarked on an international journey to Morocco.
It is understood that Walvax Biotechnology Co.Ltd(300142) is the first enterprise in China and the second enterprise in the world to obtain the listing license of 13 valent pneumonia conjugate vaccine. 13 valent pneumonia conjugate vaccine is the heavyweight vaccine with the largest sales amount in the world except covid-19 vaccine. Especially for infants and young children under 2 years old, only conjugate vaccine can have immune effect on them. At present, the global immunization coverage rate of pneumonia vaccine is only 31%, while the coverage rate of infants under 2 years old in China is lower, and there is a huge demand in the international and Chinese market.
According to the financial report data, the batch issuance volume of Walvax Biotechnology Co.Ltd(300142) 13 priced pneumococcal polysaccharide conjugate vaccine reached 4.95 million doses in 2021, a year-on-year increase of 10.88%. The sales revenue increased by 65.59% year-on-year compared with 2020. In the complex and changeable environment affected by the epidemic, the sales of its 13 valent pneumonia conjugate vaccine maintained a sustained growth.
In recent years, with the vigorous development of China Meheco Group Co.Ltd(600056) biological industry, the innovation strength and product quality of some biological pharmaceutical enterprises have entered the international top echelon, “going to sea” has become the direct goal of many pharmaceutical enterprises. Public information shows that as early as 2012, Hib vaccine, the first product of Walvax Biotechnology Co.Ltd(300142) was exported to the Philippines. So far, Walvax Biotechnology Co.Ltd(300142) of vaccine products have been exported to 17 countries around the world. In the recent annual report, Walvax Biotechnology Co.Ltd(300142) also said that it would continue to strengthen international cooperation, strengthen cooperation and exchanges with who, Gates Foundation, CEPI and other international organizations, strive to expand the international market, actively promote the registration and export of products in overseas markets, and constantly promote the implementation of the company’s comprehensive internationalization strategy.
Mr. Huang Zhen, vice chairman of Yunnan Walvax Biotechnology Co.Ltd(300142) said at the scene that from going out of Yunnan to the whole country and then to the world… Walvax Biotechnology Co.Ltd(300142) has always defined “striving to become the pride of China’s vaccine industry and the pioneer of the world’s vaccine industry” as the corporate vision.
It is worth noting that the export of 13 valent pneumonia vaccine has also been highly valued by Yuxi City, Yunnan Province. At the ceremony, relevant leaders of Yuxi City said: the Walvax Biotechnology Co.Ltd(300142) supply of 1 million doses of vaccine to the Moroccan market this time is the first overseas export of the company’s 13 valent pneumonia vaccine since its listing, which is a milestone for accelerating the internationalization of the vaccine industry in our city, It has important demonstration and driving significance for biomedical enterprises in our city to speed up key core technology research and boost the high-quality development of biomedical industry in our city.
According to public data, Yuxi City, Yunnan Province has always been the R & D and production base of 13 valent pneumonia conjugate vaccine of Walvax Biotechnology Co.Ltd(300142) . By the end of 2020, Yuxi Watson built a modern vaccine production base with an annual production capacity of 17 million doses, and completed the intelligent transformation of the vaccine Industrial Park in 2021. It is committed to building a Biotechnology Industrial Park with a global advanced level, The planned annual production capacity of 13 valent pneumonia conjugate vaccine and preparation in the industrial park is 30 million doses (stock solution + sub packaging). At present, the production is still further expanded to meet the demand of 13 valent pneumonia conjugate vaccine for export to the international market in the future.
In the field of biomedical development, the vaccine industry is both a hot spot and a key point. The Walvax Biotechnology Co.Ltd(300142) currently listed pneumonia and meningitis series vaccines, the approved bivalent HPV vaccines to be launched soon, and the pipeline markets of various vaccines under research all give high expectations. The first batch of orders from Morocco is the first step in the international sales of Walvax Biotechnology Co.Ltd(300142) 13 price pneumonia vaccine. Walvax Biotechnology Co.Ltd(300142) has taken solid steps in full internationalization, which deserves continued attention.
